<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id>
      <journal-title-group>
        <journal-title>BMC Gastroenterology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-230X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23556424</article-id>
      <article-id pub-id-type="pmc">3621100</article-id>
      <article-id pub-id-type="publisher-id">1471-230X-13-59</article-id>
      <article-id pub-id-type="doi">10.1186/1471-230X-13-59</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Adalimumab for orbital myositis in a patient with Crohn&#x2019;s disease who discontinued infliximab: a case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Verma</surname>
            <given-names>Sanam</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>sanam@ualberta.ca</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Kroeker</surname>
            <given-names>Karen I</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>karen.kroeker@ualberta.ca</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A3">
          <name>
            <surname>Fedorak</surname>
            <given-names>Richard N</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>richard.fedorak@ualberta.ca</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Division of Gastroenterology, University of Alberta, Zeidler Ledcor Center, Edmonton, Alberta, T6G 2X8, Canada</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>4</day>
        <month>4</month>
        <year>2013</year>
      </pub-date>
      <volume>13</volume>
      <fpage>59</fpage>
      <lpage>59</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>10</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>2</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Verma et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Verma et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-230X/13/59"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Orbital myositis is a rare extra-intestinal manifestation of inflammatory bowel disease. Seventeen cases of Crohn&#x2019;s disease associated orbital myositis and 3 cases of ulcerative colitis associated orbital myositis have been reported in the published literature since 1970. We report the use of adalimumab (Abbott, Canada, Inc.) for orbital myositis in a patient with Crohn&#x2019;s disease who discontinued infliximab (Janssen, Canada, Inc.) and review of the published literature.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 35 year-old male with a 7-year history of Crohn&#x2019;s disease was treated with an ileocolonic resection and re-anastomosis followed by infliximab which maintained full endoscopic and clinical remission for four years. After stopping the infliximab for infusion-related reactions he presented with 3-day history of severe right eye pain, pain with ocular movement, proptosis, and conjunctival injection. He had no intestinal symptoms and endoscopic assessment revealed no active luminal disease. CT of the orbit revealed an enlarged right medial rectus muscle with tendonous involvement and a diagnosis of orbital myositis was made. Treatment with 80 mg per day prednisone with tapering dose and adalimumab, induction and maintenance, resulted in rapid resolution of the orbital myositis and ocular symptoms with no recurrences on follow-up at 10 months.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>The current case demonstrates a rare extraintestinal manifestation of Crohn&#x2019;s disease, orbital myositis, and its temporal relationship to the discontinuance of infliximab therapy and its successful treatment, without recurrence with tapering prednisone and adalimumab.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Crohn&#x2019;s disease</kwd>
        <kwd>Ulcerative colitis</kwd>
        <kwd>Orbital myositis</kwd>
        <kwd>Extraintestinal manifestations</kwd>
        <kwd>Inflammatory bowel disease</kwd>
        <kwd>Infliximab</kwd>
        <kwd>Adalimumab</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Extra-intestinal manifestations of Crohn&#x2019;s disease (CD) are inflammatory manifestations that occur outside the gastrointestinal tract. Up to 30% of Crohn&#x2019;s patients may present with multiple extraintestinal manifestations with the occurrence of one increasing the chances of others [<xref ref-type="bibr" rid="B1">1</xref>]. Ocular manifestations of CD occur infrequently with a prevalence rate of less than 10%; most of these cases being episcleritis and uveitis [<xref ref-type="bibr" rid="B2">2</xref>]. Orbital myositis (OM) is a very rare ocular extraintestinal manifestation of CD.</p>
      <p>A literature review revealed that in a sample of 498 patients with Crohn&#x2019;s only one patient had OM [<xref ref-type="bibr" rid="B3">3</xref>]. To determine the full published literature relating to OM as a complication of CD the PubMed and Medline databases were searched for relevant literature. Seventeen previous cases of Crohn&#x2019;s related OM have been reported in literature. Only one previous study looked at adalimumab use in recurrent OM related to CD [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Therefore, in this patient group the use of adalimumab needs to be further explored.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 35-year-old Caucasian male was diagnosed with long segment ileal and extensive colonic CD in 2005, following a 10-year history of intermittent abdominal pain, cramps, and diarrhea. At diagnosis patient was placed on mesalamine (4 g/d), corticosteroids (prednisone 40 mg/d tapering over 12 weeks to zero) and azathioprine (150 mg/d) as induction therapy. He achieved clinical remission; however, within 8 months he developed an episode of small bowel obstruction and underwent an ileal resection with an ileocolonic anastomosis.</p>
      <p>Post operatively he was treated with azathioprine 150 mg/d; however, markedly elevated liver enzymes led to the discontinuance of the azathioprine. Within 6 months of stopping the azathioprine he developed recurrent abdominal pain and diarrhea and colonoscopy confirmed anastomotic recurrence of his disease. He was then started on infliximab (5 mg/kg) monotherapy with an induction regime of 0, 2, 6 weeks followed by maintenance treatment every 8 weeks. He achieved a full remission, confirmed endoscopically, for four years.</p>
      <p>After his 28<sup>th</sup> infliximab infusion, he began to develop significant arthralgia and maculaopapular skin rashes on the dorsum of his hands and arms, which worsened after each infliximab infusion. There was no biochemical evidence of disease activity; hemoglobin, C-reactive protein, platelet count, serum iron and ferritin were normal. The infliximab was discontinued and endoscopic restaging and assessment for adalimumab insurance coverage was arranged. 6-mercaptopurine (75 mg/d) was started after discontinuation of the inflximab while the endoscopic restaging and assessment was pending. However, the 6-mercaptopurine was stopped after 3 weeks due to severe nausea and fatigue. The patient&#x2019;s occupation prevented him from completing the restaging and insurance assessment and during this time he was on no therapy for his CD.</p>
      <p>Six weeks after stopping the 6-mercaptopurine and 13 weeks after stopping the infliximab the patient presented to the emergency department with a three-day history of severe right eye pain. Examination revealed an uncorrected visual acuity was 20/25 OD and 20/20 OS. Intraocular pressure of the right eye was slightly elevated, the right upper eyelid was swollen and the conjunctiva injected (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). The right globe was 1.5 mm anterior than the left. Pupillary response to light was normal and there was no relative afferent pupillary defect. The patient had limited extraocular movement and significant pain on abduction and adduction of the right eye. No optic nerve abnormalities were noted, specifically no hyperaemia of the optic nerve or nerve fiber layer edema. The patient was afebrile and had normal hemoglobin, white blood cell count, C-reactive protein, iron studies and liver function studies. Computerize tomography of the orbits revealed enlarged right medial rectus muscle with tendonous involvement, mild proptosis, no fat stranding or sclerotic changes (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>), and no sinus opacification was noted. The remaining physical exam was normal. Diagnosis of idiopathic orbital inflammatory syndrome, OM subtype, was made based on clinical findings and imaging. The patient was started on prednisone 80mg/d and tapered over 4 weeks. Within 48 hours there was improvement in the orbital pain, redness, and swelling and the patient was then started on adalimumab with induction dosing of 160 mg, 80 mg, followed by 40 mg weekly and methotrexate 12.5 mg once weekly as a standard combination therapy. Colonoscopy (after initiation of treatment of the OM) did not demonstrate active colonic or ileal disease. The OM resolved on the tapering prednisone and adalimumab and the patient has been asymptomatic on adalimumab for 10 months with no recurrence of the OM.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Patient at presentation with erythema and edema of the right upper eyelids, fullness of superior sulcus suggestive of proptosis.</p>
        </caption>
        <graphic xlink:href="1471-230X-13-59-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Computerize tomography of the orbits revealed enlarged right medial rectus muscle with tendonous insertion involvement (small arrows) and mild proptosis (large arrow).</bold> No fat stranding or scleral thickening was noted.</p>
        </caption>
        <graphic xlink:href="1471-230X-13-59-2"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>OM is a very rare extraintestinal manifestation of inflammatory bowel disease and is more common in CD than ulcerative colitis [<xref ref-type="bibr" rid="B10">10</xref>]. Seventeen previous cases of CD associated OM and three previous cases of UC related OM have been reported in literature. The clinical specifics related to these published case reports are summarized in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Published case reports (1976 &#x2013; 2012) describing orbital myositis in patients with inflammatory bowel disease</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Study author/ year</bold>
              </th>
              <th align="left">
                <bold>Age/ gender</bold>
              </th>
              <th align="left">
                <bold>IBD (CD/UC)</bold>
              </th>
              <th align="left">
                <bold>Therpay at time of orbital myositis</bold>
              </th>
              <th align="left">
                <bold>Diagnostic test confirming orbital myositis</bold>
              </th>
              <th align="left">
                <bold>Treatment for orbital myositis</bold>
              </th>
              <th align="left">
                <bold>Response to treatment</bold>
              </th>
              <th align="left">
                <bold>Follow-up</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Bennion/2012 [<xref ref-type="bibr" rid="B10">10</xref>]<hr/></td>
              <td align="left" valign="bottom">63 M<hr/></td>
              <td align="left" valign="bottom">UC<hr/></td>
              <td align="left" valign="bottom">Infliximab<hr/></td>
              <td align="left" valign="bottom">CT<hr/></td>
              <td align="left" valign="bottom">Infliximab methylprednisone<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">13 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Pimentel/2012 [<xref ref-type="bibr" rid="B9">9</xref>]<hr/></td>
              <td align="left" valign="bottom">55 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Sulfasalazine<hr/></td>
              <td align="left" valign="bottom">Gadolinium MRI<hr/></td>
              <td align="left" valign="bottom">Infliximab prednisolone<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">24 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Hernandez-Garfella/2011 [<xref ref-type="bibr" rid="B6">6</xref>]<hr/></td>
              <td align="left" valign="bottom">32 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Corticosteroids<hr/></td>
              <td align="left" valign="bottom">MRI<hr/></td>
              <td align="left" valign="bottom">Adalimumab<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">36 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Kondolt/2011 [<xref ref-type="bibr" rid="B11">11</xref>]<hr/></td>
              <td align="left" valign="bottom">11 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">CT MRI<hr/></td>
              <td align="left" valign="bottom">Corticosteroid<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Bourikas/2010 [<xref ref-type="bibr" rid="B7">7</xref>]<hr/></td>
              <td align="left" valign="bottom">35 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">MRI<hr/></td>
              <td align="left" valign="bottom">Steroids<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">12 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Culver/2008 [<xref ref-type="bibr" rid="B4">4</xref>]<hr/></td>
              <td align="left" valign="bottom">23 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Methotrexate Infliximab<hr/></td>
              <td align="left" valign="bottom">Gadolinium MRI<hr/></td>
              <td align="left" valign="bottom">Methylprednisone cyclophosphamide<hr/></td>
              <td align="left" valign="bottom">1 recurrent episode<hr/></td>
              <td align="left" valign="bottom">24 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Ramahlo/2008 [<xref ref-type="bibr" rid="B12">12</xref>]<hr/></td>
              <td align="left" valign="bottom">40 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Methotrexate 6-mercaptopurine<hr/></td>
              <td align="left" valign="bottom">MRI<hr/></td>
              <td align="left" valign="bottom">Prednisone<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Leibovitch/2005 [<xref ref-type="bibr" rid="B8">8</xref>]<hr/></td>
              <td align="left" valign="bottom">44 M<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">CT<hr/></td>
              <td align="left" valign="bottom">Prednisolone oral antibiotics<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">3 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Macarez/2005 [<xref ref-type="bibr" rid="B13">13</xref>]<hr/></td>
              <td align="left" valign="bottom">32 M<hr/></td>
              <td align="left" valign="bottom">UC<hr/></td>
              <td align="left" valign="bottom">Mesalamine<hr/></td>
              <td align="left" valign="bottom">CT MRI<hr/></td>
              <td align="left" valign="bottom">Corticosteroids<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">12 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Garrity/2004 [<xref ref-type="bibr" rid="B14">14</xref>]<hr/></td>
              <td align="left" valign="bottom">34 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Prednisone<hr/></td>
              <td align="left" valign="bottom">MRI<hr/></td>
              <td align="left" valign="bottom">Infliximab methotrexate<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">27 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Garrity/2004 [<xref ref-type="bibr" rid="B14">14</xref>]<hr/></td>
              <td align="left" valign="bottom">27 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Prednisone methotrexate 6 MP<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">Infliximab<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">27 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Maalouf/2001 [<xref ref-type="bibr" rid="B15">15</xref>]<hr/></td>
              <td align="left" valign="bottom">48 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">CT<hr/></td>
              <td align="left" valign="bottom">Prednisone<hr/></td>
              <td align="left" valign="bottom">1 recurrent episode<hr/></td>
              <td align="left" valign="bottom">96 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Jain/2001 [<xref ref-type="bibr" rid="B16">16</xref>]<hr/></td>
              <td align="left" valign="bottom">43 F<hr/></td>
              <td align="left" valign="bottom">UC<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">MRI<hr/></td>
              <td align="left" valign="bottom">Corticosteroids<hr/></td>
              <td align="left" valign="bottom">1 recurrent episode<hr/></td>
              <td align="left" valign="bottom">8 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Durno/1997 [<xref ref-type="bibr" rid="B17">17</xref>]<hr/></td>
              <td align="left" valign="bottom">12 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">MRI<hr/></td>
              <td align="left" valign="bottom">Prednisone<hr/></td>
              <td align="left" valign="bottom">3 recurrent episodes<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Squires/1992 [<xref ref-type="bibr" rid="B18">18</xref>]<hr/></td>
              <td align="left" valign="bottom">20 M<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">CT<hr/></td>
              <td align="left" valign="bottom">Prednisone<hr/></td>
              <td align="left" valign="bottom">1 recurrent episode<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Smith//1992 [<xref ref-type="bibr" rid="B19">19</xref>]<hr/></td>
              <td align="left" valign="bottom">54 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">CT<hr/></td>
              <td align="left" valign="bottom">Corticosteroid ileocolonic resection<hr/></td>
              <td align="left" valign="bottom">2 recurrent episodes<hr/></td>
              <td align="left" valign="bottom">12 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Verbraeken/1984 [<xref ref-type="bibr" rid="B20">20</xref>]<hr/></td>
              <td align="left" valign="bottom">38 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">Sulfasalazine<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">Coricosteroids Colectomy<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">2.5 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Weinstein/1984 [<xref ref-type="bibr" rid="B21">21</xref>]<hr/></td>
              <td align="left" valign="bottom">17 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">Corticosteroids IV antibiotics<hr/></td>
              <td align="left" valign="bottom">Resolved<hr/></td>
              <td align="left" valign="bottom">6 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Camfield/1982 [<xref ref-type="bibr" rid="B22">22</xref>]<hr/></td>
              <td align="left" valign="bottom">15 F<hr/></td>
              <td align="left" valign="bottom">CD<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
              <td align="left" valign="bottom">Unknown<hr/></td>
              <td align="left" valign="bottom">Corticosteroids oral antibiotics ileocolonic resection<hr/></td>
              <td align="left" valign="bottom">2 recurrent episodes<hr/></td>
              <td align="left" valign="bottom">3 months<hr/></td>
            </tr>
            <tr>
              <td align="left">Greenstein/1976 [<xref ref-type="bibr" rid="B3">3</xref>]</td>
              <td align="left">Unknown</td>
              <td align="left">CD</td>
              <td align="left">Unknown</td>
              <td align="left">Unknown</td>
              <td align="left">Unknown</td>
              <td align="left">Unknown</td>
              <td align="left">Unknown</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>CT, computerized tomography; MRI, magnetic resonance imaging; CD, Crohn&#x2019;s disease; UC, ulcerative colitis.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>OM is inflammation of one or more extraocular muscles and generally presents with the mass effect of the inflammation, leading to orbital swelling, proptosis, diplopia, chemosis, pain, injection and opthalmoplegia [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. The clinical presentation of CD-associated OM is similar to that of thyroid ophthalmopathy and as such, the pathogenesis needs to be determined early at presentation. Thyroid eye disease is typically bilateral, retracted eyelids, and has more involvement of the inferior and medial rectus while sparing tendonous insertions and appearing spindle shaped on imaging [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. In contrast, in OM associated with CD there is a tubular configuration on imaging reflecting involvement of tendonous insertion [<xref ref-type="bibr" rid="B24">24</xref>]. Furthermore, thyroid ophthalmopathy usually does not cause pain as is the case in OM. The pathophysiology of CD associated OM remains unknown, but it has been hypothesized that immune complexes form to antigenic colonic mucoproteins and may cross react with extraocular muscles [<xref ref-type="bibr" rid="B21">21</xref>].</p>
      <p>OM has been described to occur prior to the development of Crohn&#x2019;s related gastrointestinal symptoms [<xref ref-type="bibr" rid="B7">7</xref>], and when the CD is in remission [<xref ref-type="bibr" rid="B9">9</xref>]. To our knowledge this is the first case that demonstrates OM occurring in a patient in clinical and biochemical remission after discontinuation of anti-TNF&#x3B1; therapy. The fact that the onset of the OM occurred 13 weeks after stopping infliximab is in keeping with the known infliximab pharmacokinetics [<xref ref-type="bibr" rid="B25">25</xref>].</p>
      <p>Treatment of CD associated OM has traditionally involved corticosteroids as first line therapy, and low dose orbital radiotherapy, methotrexate, cyclosporine, and cyclophosphamide as second line therapies [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. While the immediate inflammatory phase of OM is frequently corticosteroid responsive recurrences may occur once the dose is tapered [<xref ref-type="bibr" rid="B5">5</xref>]. Indeed, prior to the frequent use of immunosuppressive or anti-TNF&#x3B1; therapy for CD OM recurrence was common (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>). Since the patient in this case report presented with OM after discontinuation of infliximab, there was significant risk of recurrent OM once his corticosteroid treatment tapered to zero. Infliximab was used to successfully control chronic recurrent OM in 4 patients with inflammatory bowel disease (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>) and 3 non-inflammatory bowel disease patients who all failed standard treatment [<xref ref-type="bibr" rid="B14">14</xref>]. Adalimumab was successfully utilized to treat OM in a single patient with CD who had recurrent episodes and who failed to respond to standard immunosuppression medication (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>) [<xref ref-type="bibr" rid="B6">6</xref>] and in one non-inflammatory bowel disease-related case [<xref ref-type="bibr" rid="B5">5</xref>]. Mouse chimeric nature of infliximab may lead to the development of autoantibodies and result in blunting of the clinical response and development of adverse reactions. Adalimumab, with a fully humanized molecular structure may not elicit the same autoantibody response. The CARE study efficacy of adalimumab for extraintestinal manifestations of CD and found that there is no significant difference in EIM resolution based on previous infliximab exposure [<xref ref-type="bibr" rid="B28">28</xref>].</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>The current case demonstrates a rare extraintestinal manifestation of CD, OM and its temporal relationship to the discontinuance of infliximab therapy and its successful treatment, without recurrence (for 10 months at the time of this publication), with tapering prednisone and adalimumab. Clinicians should be cognizant of this rare extraintestinal manifestation of CD that can occur in the absence of luminal disease activity, its propensity for recurrence and its successful response to anti-TNF<italic>&#x3B1;</italic> therapy.</p>
    </sec>
    <sec>
      <title>Consent statement</title>
      <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests (both financial and non-financial).</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contribution</title>
      <p>SV involved in drafting and conception of manuscript and acquisition of data. KK made substantial contributions to conception and design, analysis and interpretation of data and critical revision. RF made substantial contributions to conception and design, analysis and interpretation of data, critical revision, given final approval of the version to be published. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-230X/13/59/prepub">http://www.biomedcentral.com/1471-230X/13/59/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>This work is supported by the Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) and the Cecile Mactaggart gastrointestinal student research fund.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Caprilli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gassull</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Escher</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Moser</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Munkholm</surname>
            <given-names>P</given-names>
          </name>
          <article-title>European evidence based consensus on the diagnosis and management of Crohn's disease: special situations</article-title>
          <source>Gut March</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>i36</fpage>
          <lpage>i58</lpage>
          <pub-id pub-id-type="doi">10.1136/gut.2005.081950c</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mintz</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Feller</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Bahr</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>SA</given-names>
          </name>
          <article-title>Ocular manifestations of inflammatory bowel disease</article-title>
          <source>Inflamm Bowel Dis</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>135</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1097/00054725-200403000-00012</pub-id>
          <pub-id pub-id-type="pmid">15168814</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Greenstein</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Janowitz</surname>
            <given-names>HD</given-names>
          </name>
          <name>
            <surname>Sachar</surname>
            <given-names>DB</given-names>
          </name>
          <article-title>The extra-intestinal complications of Crohn's disease and ulcerative colitis. A study of 700 patients</article-title>
          <source>Medicine (Baltimore)</source>
          <year>1976</year>
          <volume>55</volume>
          <fpage>401</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="doi">10.1097/00005792-197609000-00004</pub-id>
          <pub-id pub-id-type="pmid">957999</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Culver</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Salmon</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Frith</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Travis</surname>
            <given-names>SP</given-names>
          </name>
          <article-title>Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn&#x2019;s disease: case report and systematic literature review</article-title>
          <source>J Crohns Colitis</source>
          <year>2008</year>
          <volume>2</volume>
          <fpage>337</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1016/j.crohns.2008.06.002</pub-id>
          <pub-id pub-id-type="pmid">21172235</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Adams</surname>
            <given-names>AB</given-names>
          </name>
          <name>
            <surname>Kazim</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lehman</surname>
            <given-names>TJ</given-names>
          </name>
          <article-title>Treatment of orbital myositis with Adalimumab (Humira)</article-title>
          <source>J Rheumatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>1374</fpage>
          <lpage>1375</lpage>
          <pub-id pub-id-type="pmid">15996084</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hernandez-Garfella</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Garcia</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Taulet</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Villanueva</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Hernandez</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>Adalimumab for recurrent orbital myositis is Crohn&#x2019;s disease: Report of a case with a 3-year follow-up</article-title>
          <source>J Crohns Colitis</source>
          <year>2011</year>
          <volume>5</volume>
          <fpage>265</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="doi">10.1016/j.crohns.2011.02.010</pub-id>
          <pub-id pub-id-type="pmid">21575896</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bourikas</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Roussomoustakaki</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Papadaki</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Valatas</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Koutroubakis</surname>
            <given-names>IE</given-names>
          </name>
          <name>
            <surname>Papadakis</surname>
            <given-names>KA</given-names>
          </name>
          <article-title>A case of orbital myositis preceding the intestinal symptoms of Crohn's disease</article-title>
          <source>J Chrons Colitis</source>
          <year>2010</year>
          <volume>4</volume>
          <fpage>349</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1016/j.crohns.2010.05.005</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Leibovitch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Galanopoulos</surname>
          </name>
          <name>
            <surname>Selva</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Suppurative Granulomatous myositis of an extra-ocular muscle in Crohn&#x2019;s disease</article-title>
          <source>American J of Gastroenterology</source>
          <year>2005</year>
          <volume>100</volume>
          <fpage>2136</fpage>
          <lpage>2137</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.50395_10.x</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="other">
          <name>
            <surname>Pimentel</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Recurrent orbital myositis as an extra-intestinal manifestation of Crohn's disease</article-title>
          <source>J Crohns Colitis</source>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1016/j.crohns.2012.05.018</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bennion</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Sivak-Callcott</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Bilateral diffuse orbital myositis in a patient with relapsing ulcerative colitis</article-title>
          <source>Ophthal Plast Reconstr Surg</source>
          <year>2012</year>
          <volume>XX</volume>
          <issue>XX</issue>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kondolot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Unal</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Poyrazoglu</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Orbital myositis associated with focal active colitis in a teenage girl</article-title>
          <source>Childs Nerv Syst</source>
          <year>2012</year>
          <volume>28</volume>
          <fpage>641</fpage>
          <lpage>643</lpage>
          <pub-id pub-id-type="doi">10.1007/s00381-011-1613-8</pub-id>
          <pub-id pub-id-type="pmid">22009155</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ramalho</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Castillo</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Imaging of orbital myositis in Crohn&#x2019;s</article-title>
          <source>Clin Imaging</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>227</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clinimag.2007.09.012</pub-id>
          <pub-id pub-id-type="pmid">18502352</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Macarez</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bazin</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Weber</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Orbital myositis associated with ulcerative colitis</article-title>
          <source>J Fr Ophthalmol</source>
          <year>2005</year>
          <volume>28</volume>
          <fpage>610</fpage>
          <lpage>13</lpage>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Garrity</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Coleman</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Matteson</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Eggenberger</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Waitzman</surname>
            <given-names>DM</given-names>
          </name>
          <article-title>Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab</article-title>
          <source>Am J Ophthalmol</source>
          <year>2004</year>
          <volume>138</volume>
          <issue>6</issue>
          <fpage>1041</fpage>
          <lpage>1043</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajo.2004.09.032</pub-id>
          <pub-id pub-id-type="pmid">15629299</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Maalouf</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Angioi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>JL</given-names>
          </name>
          <article-title>Recurrent orbital myositis and Crohn's disease</article-title>
          <source>Orbit</source>
          <year>2001</year>
          <volume>20</volume>
          <issue>1</issue>
          <fpage>75</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1076/orbi.20.1.75.2642</pub-id>
          <pub-id pub-id-type="pmid">12045937</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jain</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gottlob</surname>
            <given-names>I</given-names>
          </name>
          <article-title>Orbital myositis associated with ulcerative colitis</article-title>
          <source>Am J Gastroenterol</source>
          <year>2001</year>
          <volume>96</volume>
          <fpage>3442</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1572-0241.2001.05379.x</pub-id>
          <pub-id pub-id-type="pmid">11774970</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Durno</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Ehrlich</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Keeping an eye on Crohn's disease: orbital myositis as the presenting symptom</article-title>
          <source>Can J Gastroenterol</source>
          <year>1997</year>
          <volume>11</volume>
          <issue>6</issue>
          <fpage>497</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">9347163</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Squires</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Zwiener</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Kennedy</surname>
            <given-names>RH</given-names>
          </name>
          <article-title>Orbital myositis and Crohn's disease</article-title>
          <source>J Paediatr Gastroenterol Nutr</source>
          <year>1992</year>
          <volume>15</volume>
          <fpage>448</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="doi">10.1097/00005176-199211000-00015</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Smith</surname>
            <given-names>JW</given-names>
          </name>
          <article-title>Orbital pseudotumour and Crohn's disease</article-title>
          <source>Am J Gastroenterol Mar</source>
          <year>1992</year>
          <volume>87</volume>
          <issue>3</issue>
          <fpage>405</fpage>
          <lpage>406</lpage>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Verbraeken</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ryckaert</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Demets</surname>
            <given-names>W</given-names>
          </name>
          <article-title>Pseudotumour of the orbit and Crohn's disease</article-title>
          <source>Bull Soc Belge Ophthalmol</source>
          <year>1984</year>
          <volume>210</volume>
          <fpage>65</fpage>
          <lpage>72</lpage>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Weinstein</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Koch</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Lane</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Orbital pseudotumor in Crohn&#x2019;s colitis</article-title>
          <source>Ann Ophthalmol</source>
          <year>1984</year>
          <volume>16</volume>
          <fpage>275</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">6712071</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Camfield</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>White</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Warner</surname>
            <given-names>HA</given-names>
          </name>
          <name>
            <surname>Lythgoe</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Orbital pseudo-tumour and Crohn's disease</article-title>
          <source>J Pediatr</source>
          <year>1982</year>
          <volume>101</volume>
          <fpage>157</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="pmid">7086617</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Durno</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Ehrlich</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Keeping an eye on Crohn&#x2019;s disease: orbital myositis as the presenting symptom</article-title>
          <source>Can J Gastroenterol</source>
          <year>1997</year>
          <volume>11</volume>
          <fpage>497</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">9347163</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lacey</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Rootman</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Non-thyroid causes of extraocular muscle disease</article-title>
          <source>Surv Ophthalmol</source>
          <year>1999</year>
          <volume>44</volume>
          <fpage>187</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6257(99)00101-0</pub-id>
          <pub-id pub-id-type="pmid">10588439</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rutgeerts</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>D&#x2019;Haens</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Targan</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn&#x2019;s disease</article-title>
          <source>Gastroenterology</source>
          <year>1999</year>
          <volume>117</volume>
          <fpage>761</fpage>
          <lpage>769</lpage>
          <pub-id pub-id-type="doi">10.1016/S0016-5085(99)70332-X</pub-id>
          <pub-id pub-id-type="pmid">10500056</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Espinoza</surname>
            <given-names>GM</given-names>
          </name>
          <article-title>Orbital inflammatory pseudotumors: Etiology, differential diagnosis, and management</article-title>
          <source>Curr Rheumatol Rep</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>443</fpage>
          <lpage>447</lpage>
          <pub-id pub-id-type="doi">10.1007/s11926-010-0128-8</pub-id>
          <pub-id pub-id-type="pmid">20803107</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Smith</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Rosenbaum</surname>
            <given-names>JT</given-names>
          </name>
          <article-title>A role for methotrexate in the management of non-infectious orbital inflammatory disease</article-title>
          <source>Br J Ophthalmol</source>
          <year>2001</year>
          <volume>85</volume>
          <issue>10</issue>
          <fpage>1220</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1136/bjo.85.10.1220</pub-id>
          <pub-id pub-id-type="pmid">11567968</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>L&#xF6;fberg</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Louis</surname>
            <given-names>EV</given-names>
          </name>
          <name>
            <surname>Reinisch</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>AM</given-names>
          </name>
          <article-title>Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE</article-title>
          <source>Inflamm Bowel Dis</source>
          <year>2012</year>
          <volume>18</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <comment>Epub 2011 Feb 23</comment>
          <pub-id pub-id-type="doi">10.1002/ibd.21663</pub-id>
          <pub-id pub-id-type="pmid">21351211</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
